

Specimen Collected: 07-Nov-22 08:23

CMV Drug Resistance by NGS, |Received: 07-Nov-22 08:23 Report/Verified: 07-Nov-22 13:50
Letermovir

Procedure	Result	Units	Reference Interval
CMV Drug Resistance by NGS, Letermovir	See Note ^{f1 i1}		

Result Footnote

f1: CMV Drug Resistance by NGS, Letermovir
Letermovir,LTV Sensitive

UL56 drug resistance mutations identified: None
 UL56 additional mutations identified:V425A, N586D
 UL56 uncalled mutation sites:None

CMVResistanceCaller software version: 2.0.0.1

CMV_resistance_mutations_20220321.db

Test Information

i1: CMV Drug Resistance by NGS, Letermovir
 INTERPRETIVE INFORMATION: CMV Drug Resistance by NGS,
 Letermovir

This assay assesses resistance to letermovir. Resistance-associated mutations in the UL56 gene are sequenced using next generation sequencing. Drug resistance is assigned using an ARUP-developed database of published resistance mutations. For a list of resistance mutations refer to <https://ltd.aruplab.com/Tests/Pub/3004509>.

This test detects populations down to 10% of the total population which may account for resistance interpretation differences between methods. Some insertions or deletions may be difficult to detect using this software.

Result interpretations are as follows:

- Sensitive indicates no evidence of drug resistance compared with a wild-type virus.
- Possible resistance indicates mutations were detected with borderline-level drug resistance or conflicting resistance status reported in the literature.
- Resistant indicates evidence of drug resistance compared with a wild-type virus.
- Not determined indicates incomplete sequence coverage across a given gene or genes.
- Additional mutations include variants that have not been associated with drug resistance.
- Uncalled mutation sites include drug resistance mutation positions with an inadequate number of sequencing reads.
- Inadequate sequence coverage indicates a low number of sequence reads at a given drug resistance site.

This test was developed, and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the U.S. Food and Drug

*=Abnormal, #=Corrected, C=Critical, f=Result Footnote, H=High, i=Test Information, L=Low, t=Interpretive Text, @=Performing lab

Unless otherwise indicated, testing performed at:

ARUP Laboratories

500 Chipeta Way, Salt Lake City, UT 84108

Laboratory Director: Jonathan R. Genzen, MD, PhD

ARUP Accession: 22-311-100988

Report Request ID: 16971657

Printed: 08-Nov-22 14:46

Page 1 of 2

Patient Age/Sex: 8 hours Unknown

Test Information

i1: CMV Drug Resistance by NGS, Letermovir Administration. This test was performed in a CLIA-certified laboratory and is intended for clinical purposes.

*=Abnormal, #=Corrected, C=Critical, f=Result Footnote, H=High, i=Test Information, L=Low, t=Interpretive Text, @=Performing lab

Unless otherwise indicated, testing performed at:

ARUP Laboratories

500 Chipeta Way, Salt Lake City, UT 84108

Laboratory Director: Jonathan R. Genzen, MD, PhD

ARUP Accession: 22-311-100988

Report Request ID: 16971657

Printed: 08-Nov-22 14:46

Page 2 of 2